STOCK TITAN

Xilio Therapeutics, Inc. - XLO STOCK NEWS

Welcome to our dedicated page for Xilio Therapeutics news (Ticker: XLO), a resource for investors and traders seeking the latest updates and insights on Xilio Therapeutics stock.

Xilio Therapeutics, Inc. (Nasdaq: XLO) is a biopharmaceutical company based in Waltham, Massachusetts, dedicated to pioneering tumor-activated immuno-oncology (I-O) therapies aimed at significantly improving outcomes for cancer patients. The company's name, Xilio, is derived from the Latin term 'ex nihilo,' meaning creation or big bang, symbolizing its innovative approach.

Xilio leverages its proprietary platform to develop a pipeline of novel, tumor-activated clinical and preclinical I-O molecules. These include engineered antibodies, cytokines, and chemokines, all designed to localize anti-tumor activity within the tumor microenvironment, thus optimizing the therapeutic index and minimizing systemic side effects.

Key Products and Developments:

  • XTX202: An investigational tumor-activated, engineered IL-2 molecule designed to stimulate CD8+ effector T cells and natural killer (NK) cells without stimulating regulatory T cells. Recent Phase 1/2 data showed a 50% disease control rate at higher doses, and it is currently being evaluated in a Phase 2 trial for melanoma and renal cell carcinoma.
  • XTX101: A tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody designed to block CTLA-4 and deplete regulatory T cells within the tumor microenvironment. It is being evaluated in combination with atezolizumab in a Phase 1/2 clinical trial for advanced solid tumors.
  • XTX301: An engineered IL-12 molecule designed to boost anti-tumor immunity and convert 'cold' tumors into 'hot' ones. XTX301 is in a Phase 1 clinical trial, and Xilio has recently entered into an exclusive license agreement with Gilead Sciences for its development.

Recent Achievements:

  • XTX202 Phase 1 monotherapy dose-escalation success at a dose level of 4.0 mg/kg, with plans to explore combination therapy opportunities.
  • The company announced a strategic partnership with Gilead Sciences to accelerate the development of XTX301.
  • Financial results indicate that Xilio's existing cash and cash equivalents can fund operations into the second quarter of 2025, bolstered by recent private placements and upfront payments from strategic partnerships.

For more detailed information on Xilio Therapeutics and its pipeline of tumor-activated I-O therapies, visit www.xiliotx.com.

Rhea-AI Summary
Xilio Therapeutics, Inc. announces clinical trial collaboration with Roche to evaluate XTX101 in combination with atezolizumab in patients with colorectal cancer. The company also provides updates on its pipeline progress and financial results for Q2 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.14%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.64%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.14%
Tags
-
Rhea-AI Summary

Xilio Therapeutics (Nasdaq: XLO) announced the grant of a non-qualified stock option for 55,000 shares to Kevin Brennan, the newly appointed Senior Vice President of Finance and Accounting, effective April 1, 2023. This stock option has an exercise price of $3.17 per share, matching the closing price on March 31, 2023, and will vest in increments over four years. This action is in accordance with Nasdaq Listing Rule 5635(c)(4) and aims to incentivize Mr. Brennan's role in the company. Xilio is focused on developing tumor-activated immuno-oncology therapies to improve treatment outcomes for cancer patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.09%
Tags
none
-
Rhea-AI Summary

Xilio Therapeutics, Inc. (Nasdaq: XLO) reported progress in its clinical pipeline and financial results for 2022. The company ended 2022 with $120.4 million in cash, expected to fund operations into Q2 2024. XTX202, a tumor-activated IL-2, showed promising early results in a Phase 1 trial, with plans to initiate a Phase 2 trial in April 2023. XTX301 and XTX101 are also in development, with preliminary data anticipated in 2023. However, net losses increased to $88.2 million for the year, up from $75.8 million in 2021, driven by R&D expenses, which grew to $59.2 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.88%
Tags
Rhea-AI Summary

Xilio Therapeutics, a clinical-stage biotechnology company focused on tumor-activated immuno-oncology therapies, announced its participation in two investor conferences. The Cowen 43rd Annual Healthcare Conference will take place on March 6, 2023, at 9:10 a.m. ET, while the Oppenheimer 33rd Annual Healthcare Conference is scheduled for March 13, 2023, with a virtual presentation at 4:00 p.m. ET. Investors can access live webcasts on the Xilio Therapeutics website, with replays available for 30 days post-event. The company utilizes a proprietary platform to develop therapies aimed at improving cancer treatment outcomes without systemic side effects.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.71%
Tags
conferences
-
Rhea-AI Summary

Xilio Therapeutics, a biotechnology firm specializing in immuno-oncology therapies, announced that CEO René Russo will speak at Citi’s 2023 Virtual Oncology Leadership Summit on February 23, 2023, at 9:00 a.m. ET. The live presentation will be available on the company's website, with a replay accessible for 30 days post-event. Xilio is focused on developing tumor-activated therapies aimed at improving cancer treatment outcomes while minimizing side effects. Their innovative approach utilizes proprietary technology to target anti-tumor activity specifically within the tumor microenvironment, with multiple programs currently in clinical and preclinical stages.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.2%
Tags
conferences
-
Rhea-AI Summary

Xilio Therapeutics, Inc. (Nasdaq: XLO) announced that CEO René Russo will participate in a fireside chat at the Guggenheim Healthcare Talks Oncology Day on February 9, 2023, at 3:55 p.m. ET in New York. Investors can access a live webcast of the presentation through the Investors & Media section of the Xilio Therapeutics website. A recorded version will be available for 30 days post-event. The company focuses on developing tumor-activated immuno-oncology therapies to improve cancer treatment outcomes while reducing systemic side effects. Xilio is advancing multiple clinical and preclinical programs in this innovative area.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
conferences
Rhea-AI Summary

Xilio Therapeutics, Inc. (Nasdaq: XLO) will host a live virtual program on December 1, 2022, at 12:30 p.m. ET to discuss its clinical-stage molecule, XTX301, an engineered IL-12 aimed at treating immunologically 'cold' tumors. Dr. Diwakar Davar from UPMC Hillman Cancer Center will explain the significance of IL-12 in stimulating anti-tumor immunity and the differences between cold and hot tumors. Xilio executives will also outline the Phase 1 trial for XTX301 and its anticipated timeline. The event will include a Q&A session.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.94%
Tags
conferences

FAQ

What is the current stock price of Xilio Therapeutics (XLO)?

The current stock price of Xilio Therapeutics (XLO) is $1.469 as of November 4, 2024.

What is the market cap of Xilio Therapeutics (XLO)?

The market cap of Xilio Therapeutics (XLO) is approximately 63.3M.

What is Xilio Therapeutics, Inc.?

Xilio Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing tumor-activated immuno-oncology therapies to improve outcomes for cancer patients.

What does the name Xilio mean?

The name Xilio is derived from the Latin term 'ex nihilo,' which means creation or big bang, symbolizing the company's innovative approach.

What are the key products developed by Xilio?

Xilio's key products include XTX202 (engineered IL-2), XTX101 (anti-CTLA-4 antibody), and XTX301 (engineered IL-12).

What is the focus of Xilio's technology platform?

Xilio's technology platform focuses on developing tumor-activated I-O molecules that localize anti-tumor activity within the tumor microenvironment to optimize therapeutic index and reduce systemic side effects.

What recent achievements has Xilio reported?

Recent achievements include successful Phase 1 monotherapy dose-escalation for XTX202, a strategic partnership with Gilead Sciences for XTX301, and financial stability into the second quarter of 2025.

What is XTX202?

XTX202 is an investigational tumor-activated IL-2 molecule designed to stimulate CD8+ effector T cells and NK cells without stimulating regulatory T cells. It is in Phase 2 trials for melanoma and renal cell carcinoma.

What is XTX101?

XTX101 is a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody designed to block CTLA-4 and deplete regulatory T cells within the tumor microenvironment. It is in Phase 1/2 trials for advanced solid tumors.

What is XTX301?

XTX301 is an engineered IL-12 molecule designed to boost anti-tumor immunity and convert 'cold' tumors into 'hot' ones. It is in a Phase 1 clinical trial.

How can I learn more about Xilio Therapeutics?

For more information on Xilio Therapeutics and its pipeline, visit their official website at www.xiliotx.com.

What are the financial prospects of Xilio Therapeutics?

Xilio Therapeutics reports that its current cash and cash equivalents are sufficient to fund its operations into the second quarter of 2025, supported by recent strategic partnerships and private placements.

Xilio Therapeutics, Inc.

Nasdaq:XLO

XLO Rankings

XLO Stock Data

63.29M
43.95M
40.93%
30.22%
0.24%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WALTHAM